Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Feb 27, 2026, 4:00 PM EST
1.340
+0.020 (1.52%)
After-hours: Feb 27, 2026, 7:39 PM EST

Revelation Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Selling, General & Admin
5.014.434.515.495.04
Upgrade
Research & Development
4.063.554.155.386.91
Upgrade
Operating Expenses
9.077.988.6610.8611.95
Upgrade
Operating Income
-9.07-7.98-8.66-10.86-11.95
Upgrade
Other Non Operating Income (Expenses)
0.16-7.068.540.03-0.04
Upgrade
Pretax Income
-8.91-15.04-0.12-10.83-11.99
Upgrade
Net Income
-8.91-15.04-0.12-10.83-11.99
Upgrade
Preferred Dividends & Other Adjustments
5.95----
Upgrade
Net Income to Common
-14.87-15.04-0.12-10.83-11.99
Upgrade
Shares Outstanding (Basic)
10---
Upgrade
Shares Outstanding (Diluted)
10---
Upgrade
Shares Change (YoY)
4243.58%----
Upgrade
EPS (Basic)
-23.95-1052.23---
Upgrade
EPS (Diluted)
-23.95-1052.23---
Upgrade
Free Cash Flow
-8.27-18.34-7.29-11.22-11.22
Upgrade
Free Cash Flow Per Share
-13.32-1283.27---
Upgrade
EBITDA
-9.04-7.95-8.63-10.84-11.93
Upgrade
D&A For EBITDA
0.030.030.030.030.02
Upgrade
EBIT
-9.07-7.98-8.66-10.86-11.95
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.